What is ACUT stock price today?

ACUT (Accustem Sciences Inc) stock is trading at $0.26 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACUT stock going up or down today?

ACUT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACUT stock now?

The decision to buy ACUT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACUT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACUT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACUT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ACUT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ACUT's P/E ratio?

P/E ratio data for ACUT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ACUT's market cap?

ACUT (Accustem Sciences Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is ACUT's price to book ratio?

Price-to-book ratio for ACUT is available on our dashboard along with other valuation metrics.

Does ACUT pay dividends?

ACUT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACUT's dividend yield?

ACUT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACUT stock a good long-term investment?

ACUT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACUT's revenue growth rate?

Revenue growth data for ACUT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ACUT are available on our dashboard with complete income statement analysis.

What are the risks of investing in ACUT?

Key risks for ACUT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACUT compare to its competitors?

Compare ACUT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACUT's performance and positioning.

What is ACUT's stock price target for 2026?

Our AI model provides price targets for ACUT based on fundamental analysis: Bull case $0.33 (+30%), Base case $0.29 (+15%), Bear case $0.23 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACUT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACUT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACUT's next earnings report?

ACUT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACUT - Accustem Sciences Inc

NYSE * Healthcare * Biotechnology

$0.26

+$0.00 (+0.00%)

About Accustem Sciences Inc

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

ACUT Key Statistics

Market Cap

$4.14M

EPS

$-0.12

Employees

How ACUT Compares to Peers

ACUT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACUT(This stock)	$4.14M	N/A	0%	0.0%	-
AMGNAmgen Inc	$186.52B	24.0	0%	0.2%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.12B	26.2	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.89B	15.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$29.00B	21.1	0%	0.1%	vs BIIB

Accustem Sciences Inc Company Information

Headquarters: 5 Penn Plaza, New York, NY, United States, 10001, undefined
Website: accustem.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: June 5, 2026 at 11:04 AM EDT

Ready to invest in ACUT?

Commission-free trading available. Affiliate links.

ACUT Lician Score

5% confidence

4.0/10

Neutral

ACUT has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ACUTacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ACUT Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ACUT

Dashboard

Enter a ticker to analyze